- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
1
Posted on 11/4/24 at 12:23 pm to YungBuck
$1.80 right now
This post was edited on 11/4/24 at 12:24 pm
Posted on 11/4/24 at 12:26 pm to bulldog95
Great day. All of this due to realization that that contract news was HUGE.
1.30 --> 1.80
Or, + 38%
1.30 --> 1.80
Or, + 38%
This post was edited on 11/4/24 at 12:28 pm
Posted on 11/6/24 at 9:18 am to bayoubengals88
My lots at $0.88 looking great
Posted on 11/6/24 at 9:58 am to LSUcam7
quote:
My lots at $0.88 looking great
Will you see this one through with a high price target?
$5, $10, or $20?
Posted on 11/6/24 at 10:42 am to bayoubengals88
Just depends on results.
2022 revenues at 292M. Projected to be around 172M for this year.
Need to see continued strength in the business and ignore stock price.
2022 revenues at 292M. Projected to be around 172M for this year.
Need to see continued strength in the business and ignore stock price.
Posted on 11/6/24 at 10:57 am to LSUcam7
quote:Is this accurate? Looks too high.
2022 revenues at 292M
(Looked it up: Achieved Auryxia revenue of $177.1 million representing 24.5% growth versus 2021;
Nevermind, I see what you're saying now:
quote:
License, collaboration, and other revenue was $5.5 million for the fourth quarter of 2022 compared to $17.5 million for the fourth quarter of 2021, and $115.5 million for the full-year 2022 compared with $71.4 million for the full-year 2021. The increase for the full-year 2022 reflects a nonrefundable and non-creditable payment of $55.0 million that Otsuka paid to Akebia in July 2022 under the terms of a termination and settlement agreement between the companies. In addition, Akebia recognized $15.5 million related to previously deferred revenue as of the date of termination and $9.6 million of non-cash consideration related to Otsuka's obligations to complete certain agreed upon clinical activities. Additionally, Akebia recognized $19.1 million in collaboration revenue in 2022 from the cost sharing arrangement with Otsuka prior to the termination, compared to $53.0 million for the full-year 2021.
quote:Yes, on Auryxia alone.
Projected to be around 172M for this year.
Do you have access to any Vafseo estimates for 2025 and beyond?
This post was edited on 11/6/24 at 11:10 am
Posted on 11/7/24 at 6:48 am to bayoubengals88
Big hit PM this morning. Looks like earnings are below projected. Anyone listen to the call?
Posted on 11/7/24 at 6:53 am to reds on reds on reds
I’m pretty sure that this year’s earnings is meaningless compared to what is to come. Auryxia is their only commercial product, has been for years, and revenue is declining because it lost exclusivity recently. There’s a generic.
It’s all about what Vafseo can do starting next year. Peak sales for Auryxia were 200 million annually. Vafseo could be 10x that.
CFO just said that sales are almost exclusively focused on Vafseo.
It’s all about what Vafseo can do starting next year. Peak sales for Auryxia were 200 million annually. Vafseo could be 10x that.
CFO just said that sales are almost exclusively focused on Vafseo.
This post was edited on 11/7/24 at 7:09 am
Posted on 11/7/24 at 8:38 am to bayoubengals88
quote:I am hoping it gets beat up a little more over the next few days, if stable mid next week I will add to my position. Just watching to see how this dip shakes out.
I’m pretty sure that this year’s earnings is meaningless compared to what is to come. Auryxia is their only commercial product, has been for years, and revenue is declining because it lost exclusivity recently. There’s a generic.
Posted on 11/7/24 at 8:51 am to tigerfoot
I trimmed my AUPH position on the pop this morning and bought AKBA at 1.68
I’m comfortable with anything under my cost basis, which is around 1.70 now.
I think it’s a no brainer with the percentage of patients they have on contract.
I’m comfortable with anything under my cost basis, which is around 1.70 now.
I think it’s a no brainer with the percentage of patients they have on contract.
Posted on 11/7/24 at 10:33 am to reds on reds on reds
quote:We call that "dumb money"
Big hit PM this morning.
Posted on 11/7/24 at 11:58 am to bayoubengals88
Envious on that $1.68 pick up. I missed it. I did catch it at the $1.31 dip weeks ago for a clean haul. Holding into 2025 given all the upcoming Q1 optimism.
Posted on 11/7/24 at 1:06 pm to ynlvr
My cost basis is like 1.88. So if I grab 1200 or so more shares next week it won’t mess me up too bad.
That would give be 3500 or so shares.
That would give be 3500 or so shares.
Posted on 11/7/24 at 1:33 pm to tigerfoot
I have Plenty. Willing to take more below $1.70
Posted on 11/7/24 at 1:39 pm to tigerfoot
I'm pretty satisfied with my 3,594 now. Now we wait for $10!
Posted on 11/27/24 at 6:25 am to bayoubengals88
What are your thoughts on GSK pulling their competitor pharm (daprodustat) off the market?
Stock twits folks seem to be mostly bullish but some are saying could mean a generic is on the way.
Stock twits folks seem to be mostly bullish but some are saying could mean a generic is on the way.
Posted on 11/27/24 at 7:23 am to K9
How do yall invest into biotech and medical stocks without having a doctorate degree? Every invester needs a niche and a frame of reference. All bio tech addresses issues and complications. It's a hailmary to even get an approval and then the company performs flawlessly in an uncrowded field.
I got lucky with TMDX only because it was straightforward to the layman. The world doesn't want to transfer live organs in coolers.
I got lucky with TMDX only because it was straightforward to the layman. The world doesn't want to transfer live organs in coolers.
Posted on 11/27/24 at 8:38 am to jangalang
quote:
How do yall invest into biotech and medical stocks
I usually buy it, sell at a loss, watch it skyrocket after sale.
Posted on 11/27/24 at 9:02 am to LSUcam7
quote:
I usually buy it, sell at a loss, watch it skyrocket after sale.
That was me with several biotechs. SAVA is a horror story
Page 21 of 29
Popular
Back to top
Follow TigerDroppings for LSU Football News